Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis
- PMID: 27905897
- PMCID: PMC5131398
- DOI: 10.1186/s12879-016-2064-3
Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis
Abstract
Background: Despite improvements in treatment success rates for tuberculosis (TB), current six-month regimen duration remains a challenge for many National TB Programmes, health systems, and patients. There is increasing investment in the development of shortened regimens with a number of candidates in phase 3 trials.
Methods: We developed an individual-based decision analytic model to assess the cost-effectiveness of a hypothetical four-month regimen for first-line treatment of TB, assuming non-inferiority to current regimens of six-month duration. The model was populated using extensive, empirically-collected data to estimate the economic impact on both health systems and patients of regimen shortening for first-line TB treatment in South Africa, Brazil, Bangladesh, and Tanzania. We explicitly considered 'real world' constraints such as sub-optimal guideline adherence.
Results: From a societal perspective, a shortened regimen, priced at USD1 per day, could be a cost-saving option in South Africa, Brazil, and Tanzania, but would not be cost-effective in Bangladesh when compared to one gross domestic product (GDP) per capita. Incorporating 'real world' constraints reduces cost-effectiveness. Patient-incurred costs could be reduced in all settings. From a health service perspective, increased drug costs need to be balanced against decreased delivery costs. The new regimen would remain a cost-effective option, when compared to each countries' GDP per capita, even if new drugs cost up to USD7.5 and USD53.8 per day in South Africa and Brazil; this threshold was above USD1 in Tanzania and under USD1 in Bangladesh.
Conclusion: Reducing the duration of first-line TB treatment has the potential for substantial economic gains from a patient perspective. The potential economic gains for health services may also be important, but will be context-specific and dependent on the appropriate pricing of any new regimen.
Keywords: Cost-effectiveness; Economic evaluation; New technologies; Tuberculosis.
Figures
Similar articles
-
The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa.PLoS One. 2015 Dec 30;10(12):e0145796. doi: 10.1371/journal.pone.0145796. eCollection 2015. PLoS One. 2015. PMID: 26717007 Free PMC article.
-
Cost-effectiveness of novel first-line treatment regimens for tuberculosis.Int J Tuberc Lung Dis. 2013 May;17(5):590-6. doi: 10.5588/ijtld.12.0776. Int J Tuberc Lung Dis. 2013. PMID: 23575322 Free PMC article.
-
Economic evaluation of a shortened standardised treatment regimen of antituberculosis drugs for patients with multidrug-resistant tuberculosis (STREAM): study protocol.BMJ Open. 2016 Oct 17;6(10):e014386. doi: 10.1136/bmjopen-2016-014386. BMJ Open. 2016. PMID: 27798041 Free PMC article.
-
Tuberculosis.In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. PMID: 30212088 Free Books & Documents. Review.
-
Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.Pharmacoeconomics. 2015 Sep;33(9):939-55. doi: 10.1007/s40273-015-0279-6. Pharmacoeconomics. 2015. PMID: 25939501 Free PMC article. Review.
Cited by 11 articles
-
A Systematic Review of Economic Evaluations of Active Tuberculosis Treatments.Front Pharmacol. 2021 Dec 13;12:736986. doi: 10.3389/fphar.2021.736986. eCollection 2021. Front Pharmacol. 2021. PMID: 34966276 Free PMC article. Review.
-
Cost of TB services in healthcare facilities in Kenya (No 3).Int J Tuberc Lung Dis. 2021 Dec 1;25(12):1028-1034. doi: 10.5588/ijtld.21.0129. Int J Tuberc Lung Dis. 2021. PMID: 34886934 Free PMC article.
-
Recent Progress and Challenges for Drug-Resistant Tuberculosis Treatment.Pharmaceutics. 2021 Apr 21;13(5):592. doi: 10.3390/pharmaceutics13050592. Pharmaceutics. 2021. PMID: 33919204 Free PMC article. Review.
-
Cost-Effectiveness Analysis of BCG Vaccination against Tuberculosis in Indonesia: A Model-Based Study.Vaccines (Basel). 2020 Nov 26;8(4):707. doi: 10.3390/vaccines8040707. Vaccines (Basel). 2020. PMID: 33256143 Free PMC article.
-
Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis.Antimicrob Agents Chemother. 2021 Jan 20;65(2):e01196-20. doi: 10.1128/AAC.01196-20. Print 2021 Jan 20. Antimicrob Agents Chemother. 2021. PMID: 33229425 Free PMC article. Clinical Trial.
References
-
- World Health Organization . Global tuberculosis report 2014. Geneva: World Health Organization; 2014.
-
- Lienhardt C, Vernon A, Raviglione MC. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Curr Opin Pulm Med. 2010;16(3):186–93. - PubMed
-
- Gospodarevskaya E, Tulloch O, Bunga C, Ferdous S, Jonas A, Islam S, et al. Patient costs during tuberculosis treatment in Bangladesh and Tanzania: the potential of shorter regimens. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2014;18(7):810–7. - PubMed
MeSH terms
Substances
Grant support
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
